LARTRUVO Dosing and Administration
Treat until disease progression or unacceptable toxicity
- In study 1, patients in the LARTRUVO + doxorubicin arm who discontinued doxorubicin* were able to continue LARTRUVO monotherapy until disease progression or unacceptable toxicity
- Do not administer LARTRUVO as an IV push or bolus
- Refer to doxorubicin prescribing information for dosing and dose modifications
*Discontinuation due to either unacceptable doxorubicin-related toxicity or upon completion of 8 cycles.
Flexible dosing options
LARTRUVO injections (10 mg/mL)
A retrospective analysis reviewed 2,285 patients with STS, calculated the dose needed for each patient, and estimated the average waste associated with dispensing LARTRUVO 500 mg/50 mL vials. The average waste per patient per administration was approximately 234 mg. Using a combination of 190 mg/19 mL and 500 mg/50 mL vials, the average waste per patient per administration was reduced to 29 mg, an 87.6% reduction.1
Vial selection guide
The table below can help identify the most appropriate vial size for your patients.*
*Depending on the weight-based dose, the full amount in the vials may not be used.
Infusion-related reactions (IRR)
IRR occurred in 70 (14%) of 485 patients who received at least one dose of LARTRUVO across clinical trials. For 68 of these 70 patients (97%), the first occurrence of IRR was in the first or second cycle. Grade ≥3 IRR occurred in 11 (2.3%) of 485 patients, with one (0.2%) fatality. Symptoms of IRR included flushing, shortness of breath, bronchospasm, or fever/chills, and in severe cases symptoms manifested as severe hypotension, anaphylactic shock, or cardiac arrest. IRR required permanent discontinuation in 2.3% of patients and interruption of infusion in 10% of patients. All 59 patients with Grade 1 or 2 IRR resumed LARTRUVO; 12 (20%) of these patients had a Grade 1 or 2 IRR with rechallenge. The incidence of IRR in the overall safety database (N=485) was similar (18% versus 12%) between those who did (56%) and those who did not (44%) receive premedication. Monitor patients during and following LARTRUVO infusion for signs and symptoms of IRR in a setting with available resuscitation equipment. Immediately and permanently discontinue LARTRUVO for Grade 3 or 4 IRRs.
Premedicate with diphenhydramine (25 mg to 50 mg intravenously) and dexamethasone (10 mg to 20 mg intravenously) prior to LARTRUVO on Day 1 of Cycle 1.
LARTRUVO dose modifications
- Permanently discontinue LARTRUVO for Grade 3 or 4 IRR
- Interrupt infusion of LARTRUVO for Grade 1 or 2 IRRs. After resolution, resume LARTRUVO infusion at 50% of the initial infusion rate
- For neutropenic fever/infection or Grade 4 neutropenia lasting longer than 1 week, discontinue administration of LARTRUVO until the absolute neutrophil count is 1,000/microliter or greater and then permanently reduce the dose to 12 mg/kg